GlassScriptPhysician profile
Joshua A Donis
NPI 1770569048
$5,239.58
in general payments reported to CMS, 2019-2025
31 companies · $889 in 2025
The $889 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,499 · 2020: $407 · 2021: $496 · 2022: $663 · 2023: $779 · 2024: $505 · 2025: $889.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,173.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,173.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $732.92 | 2019-2025 | Lifevest |
| Amgen INC. | $641.47 | 2019-2024 | Repatha |
| Janssen Pharmaceuticals, INC | $618.25 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $585.25 | 2019-2025 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $472.10 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $302.59 | 2019-2025 | Farxiga, Andexxa |
| Pfizer INC. | $292.96 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $255.05 | 2022-2025 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $211.93 | 2019-2025 | Jardiance |
| Abbott Laboratories | $171.53 | 2021-2023 | Cardiomems |
| Bayer Healthcare Pharmaceuticals INC. | $151.28 | 2021-2025 | |
| Boston Scientific Corporation | $127.50 | 2019-2021 | |
| Medtronic, INC. | $126.72 | 2022-2024 | Venaseal |
| Shockwave Medical, INC | $114.87 | 2022-2025 | |
| Philips North America LLC | $59.73 | 2023 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $38.29 | 2025 | Sapien 3 Ultra Resilia |
| Amarin Pharma, INC. | $36.74 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $31.11 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $30.57 | 2019 | |
| Esperion Therapeutics, INC. | $27.49 | 2021 | |
| Ionis Pharmaceuticals, INC. | $25.85 | 2025 | Tryngolza |
| Medtronic Vascular, INC. | $22.68 | 2019 | |
| Vital Connect, INC | $22.35 | 2024 | Vitalpatch Rtm |
| Lantheus Medical Imaging, INC. | $19.30 | 2025 | |
| Novo Nordisk INC | $18.83 | 2025 | Wegovy |
| Dilon Technologies, INC. | $18.73 | 2023 | Hemoblast Bellows |
| Bridgebio Pharma, INC. | $18.57 | 2025 | Attruby |
| Inspire Medical Systems, INC. | $17.92 | 2025 | Inspire |
| Lexicon Pharmaceuticals, INC. | $17.57 | 2023 | Inpefa |
| Elutia, INC. | $16.84 | 2021 | |
| Amryt Pharma Holdings LTD | $12.59 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joshua Donis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.